HIND
HEALTHCAREReShape Lifesciences Inc
$2.20+0.13 (+6.28%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving HIND Today?
No stock-specific AI insight has been generated for HIND yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.75$33.16
$2.20
Fundamentals
Market Cap$15M
P/E Ratio—
EPS$-4.86
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume31K
Avg Volume (10D)—
Shares Outstanding7.0M
HIND News
20 articles- Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026Yahoo Finance·Apr 22, 2026
- Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026Yahoo Finance·Apr 6, 2026
- Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...Yahoo Finance·Mar 30, 2026
- Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout PhaseYahoo Finance·Mar 26, 2026
- Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics CompanyYahoo Finance·Feb 24, 2026
- Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market OpportunityYahoo Finance·Feb 18, 2026
- Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 MonthsYahoo Finance·Feb 11, 2026
- Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 ResultsYahoo Finance·Feb 2, 2026
- Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 StudyYahoo Finance·Jan 27, 2026
- We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn RateYahoo Finance·Dec 29, 2025
- Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated CompanyYahoo Finance·Dec 22, 2025
- Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA ApprovalYahoo Finance·Dec 8, 2025
- Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW ProgramYahoo Finance·Nov 25, 2025
- Vyome Holdings Announces Transformational First Quarter Following Nasdaq ListingYahoo Finance·Nov 18, 2025
- Vyome Holdings Announces Results of Annual Shareholder MeetingYahoo Finance·Nov 4, 2025
- Vyome Holdings Acquires MIT AI Spinout Oculo HealthYahoo Finance·Sep 29, 2025
- Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market OpportunityYahoo Finance·Sep 17, 2025
- Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunityYahoo Finance·Sep 4, 2025
- Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation StudioYahoo Finance·Aug 21, 2025
- Vyome Announces Strategic Review of Livechain (OTCID: LICH)Yahoo Finance·Aug 18, 2025
All 20 articles loaded
Price Data
Open$2.10
Previous Close$2.07
Day High$2.30
Day Low$2.10
52 Week High$33.16
52 Week Low$1.75
52-Week Range
$1.75$33.16
$2.20
Fundamentals
Market Cap$15M
P/E Ratio—
EPS$-4.86
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume31K
Avg Volume (10D)—
Shares Outstanding7.0M
About ReShape Lifesciences Inc
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company is headquartered in Princeton, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—